Coxibs, science, and the public trust.
- 24 January 2005
- journal article
- editorial
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 165 (2), 158-60
- https://doi.org/10.1001/archinte.165.2.158
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes MellitusArchives of Internal Medicine, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart diseaseThe Lancet, 2002
- Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial InfarctionArchives of Internal Medicine, 2002
- Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.Archives of Internal Medicine, 2002
- Association between naproxen use and protection against acute myocardial infarction.Archives of Internal Medicine, 2002
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research DesignsNew England Journal of Medicine, 2000